ABLYNX – Nanobodies – Turnarond on the Horizon!

US$ 140

Partnering of ALX-0061 (PhI/II, Anti-IL6R, RA) with AbbVie under attractive terms (deal value of $840m/~€630m) and news flow in last one year brought back Ablynx (ABLX) and its nanobody platform’s’ potential in the limelight!

07-16 2015   Pages: 7

Rituximab biosimilar

US$ 2000

Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several other conditions and had $2 billion in sales in Europe last year.

07-16 2015   Pages: 45

Hepatitis C Virus Infection

US$ 1000

Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead’s Sofosbuvir/RBV

07-16 2015   Pages: 33

Dietary Supplements: World of Opportunities In the Indian Healthcare Market

US$ 2000

Increasing rate of chronic diseases has emphasized the need of Prevention over Intervention. These proactive health solutions include nutritional supplements which promise medical or health benefits and fall between the food and pharma chain – ‘Nutraceuticals’.

07-16 2015   Pages: 62

New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan

US$ 4000

The launch of Remicade biosimilar in Dec-2014 in the Japan pharma market demonstrated its changing regulatory environment; it is faster than U.S. in adapting to biosimilar use. After nine years of continuous efforts by the JP government to promote increased use of generics

07-16 2015   Pages: 65

Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure

US$ 3000

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing the life expectancy WW.

07-16 2015   Pages: 98

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

US$ 3000

While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes,

07-16 2015   Pages: 82

Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain

US$ 3000

Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined.

07-16 2015   Pages: 65
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample